O

Option Care Health

Largest independent home infusion therapy provider

Sterile Compounding Quality Manager

Full-Time
$100k - $166.6k
Senior
Springfield, IL, USA
HybridTravel up to 50% of the time for business, within and outside the state.
Medical, Clinical & VeterinaryPharmacy

About the job

Requirements
  • Hold either a Compounded Sterile Preparation Technician (CSPT) certification through the PTCB or a Board Certified Sterile Compounding Pharmacist (BCSCP) certification through BPS.
  • Hold pharmacy technician licensure or registration as granted by the home state, or an active and unrestricted pharmacist license.
  • Have 7 years of experience in infusion therapy, sterile compounding, training, creating presentations, creating forms and policies, or another equivalent corporate office environment.
  • Use time-management skills to prioritize, organize, and track details and meet deadlines across multiple projects with varying completion dates.
  • Have at least 3 years of experience analyzing and reporting data to identify issues, trends, or exceptions, drive improvement of results, and find solutions.
  • Have intermediate to upper-intermediate proficiency with Microsoft Outlook, Word, PowerPoint, and Excel.
  • Have at least 3 years of experience identifying operational issues and recommending and implementing strategies to resolve problems.
  • Have at least 3 years of experience in direct or indirect management of team members, including assisting with their development and training and assigning work or projects.
  • Have at least 7 years of relevant pharmacy technician or pharmacist experience in a home infusion pharmacy or large sterile compounding cleanroom.
  • Be able to sit and work on a laptop or personal computer for extended periods and enter a cleanroom without compromising the quality of sterile preparations.
  • Be willing to travel up to 50% of the time for business within and outside the state.
Responsibilities
  • Provide field subject-matter support for cleanroom quality questions and assistance during urgent cleanroom quality incidents, including involving appropriate leadership and assisting with quality clinical decisions under company policy.
  • Maintain and review cleanroom quality systems and tools, and provide routine and directed reports and executive summaries.
  • Coordinate with the cleanroom facilities team and local leadership to schedule certifications and ensure reports are reviewed and microbial monitoring maps are current, accurate, and aligned with regulatory and operational requirements.
  • Review key performance indicators and quality systems and tools for trends, and assist in developing proactive and preventive initiatives for sterile compounding practices.
  • Provide standard and ad hoc reports on quality improvement activities and adherence to quality metrics, and assist with pharmacy metrics and reports using relevant data sources.
  • Lead root-cause investigations, identify systemic risks and contributing factors, and develop, coordinate, and monitor corrective and preventive action plans with management and stakeholders to support effective resolution and continuous improvement.
  • Conduct quality visits to assess cleanroom conditions, provide cleanroom quality training, and communicate findings and action plans to corporate or field management, legal, and accreditation personnel as needed.
  • Support new cleanroom construction and remodel initiatives with quality and clinical guidance, and collaborate with stakeholders to develop and implement compliant and effective procedures, workflows, and controls.
  • Build and maintain vendor relationships with management and provide vendor-intervention support when needed for field cleanroom quality.
  • Assist in developing action plans based on Board of Pharmacy or other agency inspections, accreditation findings, and internal quality indicators, recommendations, and guidelines.
  • Assist in developing and maintaining policies, procedures, and training materials for sterile compounding and cleanroom quality based on company standards and federal and state regulations.
  • Partner with Clinical Education to create training materials and tools for orientations and training programs concerning sterile compounding, cleanroom maintenance, and regulatory compliance.
  • Build and maintain relationships with team members across the company.
  • Support continuous improvement, innovation, efficiency, and standardization.
Desired Qualifications
  • Experience evaluating information to determine compliance with standards, laws, and regulations.
  • Active participation in professional organizations.

About the company

Option Care Health delivers infusion therapies at home and other alternate-site locations across the United States, supported by over 7,000 teammates including about 4,500 clinicians. Clinicians visit patients at home or approved sites to administer therapies, manage care, and coordinate with care teams under strong clinical leadership and national scale. It stands out as the largest independent infusion provider with nationwide reach and a robust clinical workforce, enabling scalable home and alternate-site infusion rather than hospital-only care. The goal is to elevate standards of care and reimagine the infusion care experience by expanding access, improving outcomes, and delivering compassionate, clinically driven service.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bannockburn, Illinois

Founded

1979

Get referred to Option Care Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 29, 2026 Q2 revenue reached $1.44 billion, while acute therapy and IG Neuro strengthened.
  • Management stabilized CID patient census in Q2 2026 and kept full-year revenue guidance unchanged.
  • The company repurchased $150 million in Q2 2026, signaling confidence and shareholder-return capacity.

What critics are saying

  • August 2026 guidance still bakes in a 600-basis-point CID revenue headwind and $55 million gross profit hit.
  • July 29, 2026 Q2 buyback of $150 million masks weak top-line momentum and analyst skepticism.
  • Biosimilar erosion and payer reverification pressure can permanently shrink chronic volumes if retention stays broken.

What makes Option Care Health unique

  • Option Care Health leads U.S. independent home and alternate-site infusion, with nationwide clinician density.
  • Its payer, biopharma, and prescriber relationships create switching costs across chronic and acute therapies.
  • August 27, 2026 guidance shows durable cash generation, with at least $320 million operating cash flow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Paid Time Off
  • Bonding Time Off
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Health Savings Account/Flexible Spending Account
  • Flexible Spending Accounts
  • Tuition Reimbursement
  • Family Support
  • Mental Health Support

Company News

AD HOC NEWS
Oct 15th, 2026
McKesson commits $1.4B for 49% stake in Option Care at $5.8B valuation

McKesson will invest $1.4 billion for a 49% minority stake in Option Care Health, under an agreement announced on October 6, 2026. The deal values Option Care at an enterprise value of $5.8 billion. Clayton, Dubilier & Rice will hold about 51%. Option Care will stay separately managed, while McKesson keeps a framework to acquire the remaining interest later, subject to conditions and regulatory approvals. In its first fiscal 2027 quarter, McKesson reported revenue of $105.38 billion, up 7.7% year on year, and adjusted earnings per share of $9.93. It will report second-quarter results on November 4, 2026.

Yahoo Finance
Oct 6th, 2026
McKesson and Clayton Dubilier & Rice near $5B deal to acquire Option Care Health

Option Care Health shares jumped 33.2% in pre-market trading after the Financial Times reported McKesson and Clayton Dubilier & Rice are nearing a transaction valued at over $5 billion to acquire the alternate site health provider. According to the report, the deal would involve the two firms partnering to buy the infusion services provider, which they view as undervalued. Large-scale buyout discussions typically drive market optimism as investors anticipate acquisition premiums. The move is significant for Option Care Health, whose shares have experienced 13 movements greater than 5% over the past year. At $31.03 per share, the stock is trading 15.2% below its 52-week high but remains down 3.8% year-to-date.

Central Charts
Oct 6th, 2026
CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health

CD&R, McKesson Corporation (NYSE: MCK) (“McKesson”), and Option Care Health, Inc. (Nasdaq: OPCH) (“Option Care Health”) announced today that they have

Yahoo Finance
Jul 29th, 2026
Option Care Health Q2 beats expectations with $1.4B revenue, narrows full-year guidance

Option Care Health reported second-quarter 2026 results that exceeded expectations. Revenue rose 7% sequentially to $1.4 billion, whilst adjusted EBITDA increased 12% to $117.5 million and adjusted EPS reached $0.45. Operating cash flow totalled $184 million. Acute therapies posted high-single-digit organic growth, while chronic revenue improved sequentially as the CID portfolio began to stabilise. However, CID-related pressure is expected to reduce 2026 revenue by roughly 600 basis points and gross profit by $55 million. The home and alternate-site infusion provider maintained its full-year revenue guidance at $5.675 billion to $5.775 billion. Adjusted EBITDA guidance was narrowed to $480 million to $495 million, and adjusted EPS guidance to $1.85 to $1.92. The company repurchased $150 million of shares, nearly 5% of shares outstanding.

Yahoo Finance
Jul 29th, 2026
Option Care Health reports $1.44B Q2 revenue, up 1.9%, and raises $150M share buyback

Option Care Health, the largest independent provider of home and alternate site infusion services in the US, reported second quarter 2026 results. Net revenue reached $1.44 billion, up 1.9% year-over-year. The company posted net income of $53.9 million, up 6.7%, with diluted earnings per share of $0.35, up 12.9%. Adjusted EBITDA grew 3.0% to $117.5 million. The company repurchased $150 million of outstanding shares during the quarter. For full year 2026, Option Care Health expects net revenue between $5.68 billion and $5.78 billion, with adjusted diluted earnings per share of $1.85 to $1.92. The company forecasts adjusted EBITDA of $480 million to $495 million and operating cash flow of at least $320 million.